Two recent studies highlight the importance of physical activity volume and intensity in reducing cardiovascular disease (CVD) risk and improving longevity.
The first study analyzed data from over 24,000 middle-aged and older non-exercisers in the UK Biobank, examining the effects of incidental physical activity (IPA)—unstructured daily movement outside formal exercise—on CVD and mortality. Using accelerometry, researchers categorized IPA into vigorous (VIPA), moderate (MIPA), and light (LIPA) intensities. Over nearly 8 years of follow-up, higher IPA levels, particularly VIPA and MIPA, were associated with significantly lower risks of major CVD events and death.
Key findings:
These results underscore that even brief bouts of vigorous or moderate incidental activity can substantially benefit cardiovascular health, especially for individuals unable to engage in structured exercise.
The second study, involving over 26,000 adults linked to Medicare records, explored how different physical activity (PA) levels influence coronary artery disease (CAD) and mortality. Researchers found:
The takeaway: Moderate exercise may offer optimal protection against CAD, while high-volume exercise enhances longevity but does not necessarily mitigate clinical CAD risk if CAC is present.
Both studies reinforce that moderate-intensity activity on most days is highly beneficial for cardiovascular health and longevity. Intensity and consistency appear more critical than structured exercise, with even small amounts of vigorous incidental activity yielding significant benefits. Source: https://www.ahajournals.org/
A study revealed that stroke remains a major global health challenge, influenced by numerous risk…
A systematic review and meta-analysis evaluated randomized controlled trials on pharmacological treatments for anxiety in…
A global study suggested that most patients with coronary heart disease (CHD) have Lipoprotein (a)…
A recent article explored the science and skepticism surrounding seed oils. These oils—extracted from sources…
A Canadian study of adults with high blood pressure (BP) found no difference in health…
Two randomized, controlled trials evaluated the efficacy and safety of obicetrapib, an oral cholesteryl ester…
This website uses cookies.